Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients

Lignende værker

• Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
  af: Cho, Kyoung Min, et al.
  Udgivet: (2015)
• How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
  af: Keam, Bhumsuk, et al.
  Udgivet: (2013)
• Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
  af: Sim, Sung Hoon, et al.
  Udgivet: (2015)
• Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  af: Keam, Bhumsuk, et al.
  Udgivet: (2014)
• The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
  af: Lee, June-Koo, et al.
  Udgivet: (2015)